Flag of the European Union EU Clinical Trials Register Help

Clinical trials for cystic fibrosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    139 result(s) found for: cystic fibrosis. Displaying page 7 of 7.
    « Previous 1  2  3  4  5  6  7 
    EudraCT Number: 2013-002202-31 Sponsor Protocol Number: POL7080-002 Start Date*: 2013-09-11
    Sponsor Name:Polyphor Ltd.
    Full Title: A phase II, open-label, multi-center study to assess the tolerance, safety, efficacy and pharmacokinetics/pharmacodynamics (PK/PD) of POL7080 in the treatment of patients with acute exacerbation of...
    Medical condition: Acute exacerbation of non-cystic fibrosis bronchiectasis due to Pseudomonas aeruginosa infection.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004334-13 Sponsor Protocol Number: MSI-1995-203 Start Date*: 2005-04-08
    Sponsor Name:Genaera Corporation
    Full Title: A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Talniflumate in Cystic Fibrosis Subjects
    Medical condition: Cystic Fibrosis
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003628-39 Sponsor Protocol Number: TNS0107 Start Date*: 2007-11-22
    Sponsor Name:ECUPHARMA S.R.L.
    Full Title: Pilot study to evaluate the local tollerability and efficacy of a new tobramycin 3% nasal spray formulation to reduce the bacterial density of Pseudomonas aeruginosa and/or Staphylococcus aureus, i...
    Medical condition: Rhinosinusal infection by Pseudomonas a. e/o Staphylococcus a. in patients with Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024970 Respiratory tract infections HLGT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-003040-39 Sponsor Protocol Number: CTBM100G2202 Start Date*: 2016-09-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, blinded, parallel group, multi-center dose-finding study, to assess the efficacy, safety and tolerability of different doses of tobramycin inhalation powder in patients with Non-Cysti...
    Medical condition: Pseudomonas aeruginosa infection in patients with non-cystic fibrosis bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10006445 Bronchiectasis PT
    19.0 10021881 - Infections and infestations 10070295 Infective exacerbation of bronchiectasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) BE (Completed) DE (Completed) IE (Completed) NL (Completed) GB (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014412-35 Sponsor Protocol Number: ARD-3100-0901 Start Date*: 2010-02-23
    Sponsor Name:Aradigm Corporation
    Full Title: An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Administration of Two Strengths of Ciprofloxacin f...
    Medical condition: Non-cystic fibrosis bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10006446 Bronchiectasis NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000243-87 Sponsor Protocol Number: PC_ASP_003 Start Date*: 2018-11-19
    Sponsor Name:Pulmocide Ltd
    Full Title: An open-label study to assess the safety, pharmacokinetics and pharmacodynamics of inhaled PC945 in adult Cystic Fibrosis (CF) patients with persistent pulmonary Aspergillus fumigatus infection.
    Medical condition: Pulmonary aspergillosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10059259 Pulmonary aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-002362-37 Sponsor Protocol Number: GlaxoSmithKline, B2C101762 Start Date*: 2004-12-22
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A multicentre, randomised, double-blind, placebo-controlled, dose ascending, four way crossover study to examine efficacy (FEV1),safety, tolerability, pharmacodynamics and pharmacokinetics of sing...
    Medical condition: GW642444 is a new potent and selective inhaled beta-2-receptor agonist, which is being developed for once daily treatment of asthma and COPD.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000817-30 Sponsor Protocol Number: TICTAC-2014 Start Date*: 2014-08-14
    Sponsor Name:University Medical Centre Utrecht
    Full Title: Comparing the effect of curcumin and genistein to treatment with Ivacaftor in CF patients with a class III mutation
    Medical condition: Cystic Fibrosis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-004491-18 Sponsor Protocol Number: BAY85-8501-16359 Start Date*: 2013-01-30
    Sponsor Name:Bayer HealthCare AG
    Full Title: A Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety and Efficacy of 28 Day Oral Administration of BAY 85-8501 in Patients with non-Cystic Fibrosis B...
    Medical condition: Non-Cystic Fibrosis Bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    15.1 10038738 - Respiratory, thoracic and mediastinal disorders 10006445 Bronchiectasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001891-19 Sponsor Protocol Number: B2F104302 Start Date*: 2006-09-28
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A multi-centre, randomised, dose-ascending, double-blind, placebo-controlled, four-way incomplete block crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokine...
    Medical condition: Asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005329-68 Sponsor Protocol Number: B2E106359 Start Date*: 2006-03-17
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A multi-centre, randomised, double-blind, placebo-controlled, four-way incomplete crossover study to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of single and repe...
    Medical condition: Persistent asthmatic subjects
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-002390-25 Sponsor Protocol Number: E21-04 Start Date*: 2022-01-20
    Sponsor Name:Fab'entech
    Full Title: A two-stage randomized, placebo-controlled, double-blind, phase 2a study to characterize the safety and pharmacokinetics of FBR-002 in patients hospitalized with COVID-19 need of supplemental oxyge...
    Medical condition: COVID-19 in hospitalized patients in need of supplemental oxygen and at risk of severe outcome
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001862-56 Sponsor Protocol Number: 64041575RSV2004 Start Date*: 2018-01-09
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (...
    Medical condition: Respiratory syncytial virus infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) BE (Prematurely Ended) FI (Prematurely Ended) SK (Prematurely Ended) ES (Prematurely Ended) IE (Prematurely Ended) PT (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000050-10 Sponsor Protocol Number: FORMaT001 Start Date*: 2023-01-02
    Sponsor Name:University of Queensland
    Full Title: Finding the Optimal Regimen for Mycobacterium abscessus Treatment
    Medical condition: Mycobacterium abscessus pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10064789 Mycobacterium abscessus infection PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001641-79 Sponsor Protocol Number: 64041575RSV2001(ALS-8176-505) Start Date*: Information not available in EudraCT
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, Viral Kinetics, and Pharmacokinetics of Orally Administer...
    Medical condition: Respiratory Syncytial Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002840-26 Sponsor Protocol Number: CQBW251C12201 Start Date*: 2020-12-22
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, subject- and investigator-blinded, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of QBW251 in patients with bronch...
    Medical condition: Bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004855 10083611 Non-cystic fibrosis bronchiectasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004419-31 Sponsor Protocol Number: B2C106093 Start Date*: 2006-03-24
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A multi-centre, randomised, double-blind, placebo-controlled, four-way incomplete block crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of single a...
    Medical condition: Asthma and Chronic Obstructive Pulmonary Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-014594-40 Sponsor Protocol Number: D0520C00014 Start Date*: 2010-02-04
    Sponsor Name:AstraZeneca AB
    Full Title: A 12-week, Phase-II, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multi-Centre Study to Assess the Effect of 60 mg AZD9668 Administered Orally Twice Daily on Structural Changes in ...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2022-002724-12 Sponsor Protocol Number: E22-04 Start Date*: 2022-11-24
    Sponsor Name:Fab'entech
    Full Title: A phase IIb randomized, placebo-controlled, double-blind study, to evaluate the efficacy and safety of FBR-002 in participants hospitalized with COVID-19 in need of supplemental oxygen and at risk ...
    Medical condition: COVID-19 in hospitalized patients in need of supplemental oxygen and at risk of severe outcome
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jul 21 08:12:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA